Neurocrine Biosciences Inc (NBIX)
Current ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Total current assets | US$ in thousands | 1,724,700 | 1,607,000 | 1,453,500 | 972,800 | 1,016,200 |
| Total current liabilities | US$ in thousands | 507,700 | 654,800 | 537,700 | 245,800 | 186,500 |
| Current ratio | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 |
December 31, 2024 calculation
Current ratio = Total current assets ÷ Total current liabilities
= $1,724,700K ÷ $507,700K
= 3.40
The current ratio of Neurocrine Biosciences Inc has experienced a declining trend over the past five years. Starting from a high of 5.45 in December 31, 2020, the ratio has gradually decreased to 3.40 by December 31, 2024. This indicates that the company's current assets may not be sufficient to cover its current liabilities as effectively as in the past. While a current ratio above 2 is generally considered healthy, the downward trajectory suggests a potential weakening in the company's short-term liquidity position. Further analysis of the components comprising current assets and liabilities may provide insights into the specific factors driving this trend.
Peer comparison
Dec 31, 2024